2004 OMIG, Abstract 11

OMIG Main Page | 2004 Abstracts | < Previous | Next >

Comparison of In-Vitro Resistant Rates of Daptomycin and the Ophthalmic Fluoroquinolones Against Methicillin Resistant Staphylococcus aureus (MRSA) Ocular Isolates
S Meskin, TL Kaiura, M Shah, D Ritterband, D Shapiro, J Seedor. New York Eye and Ear Infirmary Department of Ophthalmology, New York, New York

Purpose: To study the in-vitro susceptibility profiles of Daptomycin, a novel lipopeptide antibiotic, against ocular isolates of Methicillin Resistant Staphylococcus Aureus (MRSA).
Methods: 65 MRSA ocular isolates archived at the New York Eye and Ear Infirmary (NYEEI) from cases of corneal ulcer or endophthalmitis were tested for in vitro susceptibility against daptomycin, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin and ciprofloxacin.
Results: In vitro resistance rates for MRSA isolates in descending order were ofloxacin (59/65, 91%) and ciprofloxacin (59/65, 91%), gatifloxacin (48/65, 74%), moxifloxacin (46/65, 71%), daptomycin (3/65, 4.6%). 46 of 65 (71%) MRSA ocular isolates were resistant to all the fluoroquinolones tested. 3 of 65 (4.6%) were resistant to daptomycin.
Conclusions: Daptomycin is the first in the class of lipopeptide antimicrobials to be approved for treatment of MRSA related skin and soft tissue infections. To date resistance has not been reported. With increasing evidence of resistance of MRSA ocular isolates to currently available ophthalmic fluoroquinolones, daptomycin may be a new therapeutic alternative against ocular MRSA strains.

Disclosure code: N

OMIG Main Page | 2004 Abstracts | < Previous | Next >